FDA head calls for inquiry into Alzheimer’s drug review

FDA head calls for inquiry into Alzheimer's drug review
This image provided by Biogen on Monday, June 7, 2021 shows a vial and packaging for the drug Aduhelm. On Friday, July 9, 2021, the acting head of the U.S. Food and Drug Administration called for a government investigation into highly unusual contacts between some of her agency’s drug reviewers and the maker of the controversial new Alzheimer’s drug. Credit: Biogen via AP, File

The acting head of the Food and Drug Administration on Friday called for a government investigation into highly unusual contacts between her agency’s drug reviewers and the maker of a controversial new Alzheimer’s drug.

Dr. Janet Woodcock announced the extraordinary step via Twitter. It’s…

Read more…